Comparative Pharmacology
Head-to-head clinical analysis: LIBERVANT versus MENRIUM 10 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIBERVANT versus MENRIUM 10 4.
LIBERVANT vs MENRIUM 10-4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-A receptor positive allosteric modulator; enhances inhibitory neurotransmission.
Mennium 10-4 is a combination of chlordiazepoxide, a benzodiazepine that enhances GABA-A receptor activity, and clidinium, an antimuscarinic that blocks muscarinic acetylcholine receptors.
0.25 mg intravenously over 2 minutes, may repeat once after 15 minutes if inadequate response; maximum total dose 0.5 mg.
Adults: 1 tablet (chlordiazepoxide 10 mg / clidinium 4 mg) orally 3 to 4 times daily before meals and at bedtime. Max: 4 tablets per day.
None Documented
None Documented
Terminal elimination half-life is approximately 2–4 hours in patients with normal renal function; may be prolonged up to 8–12 hours in severe renal impairment (CrCl <30 mL/min).
Chlordiazepoxide: 5-30 h (mean 20 h); clidinium: 10-20 h. Steady-state reached in 5-7 days.
Primarily renal excretion of unchanged drug (approximately 85%) and glucuronide conjugates (approximately 10%); biliary/fecal excretion accounts for less than 5%.
Renal (60% as unchanged chlordiazepoxide, 15% as conjugated metabolites; 5% biliary/fecal as metabolites)
Category C
Category C
Benzodiazepine
Benzodiazepine/Estrogen Combination